University Hospitals Bristol NHS Foundation Trust
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Private
- Employees
- -
- Market Cap
- -
- Website
- http://www.uhbristol.nhs.uk
Cemiplimab Plus Chemotherapy Shows Promise in Advanced Penile Cancer EPIC Trial
• Phase 2 EPIC trial demonstrates 62.1% clinical benefit rate at 12 weeks for cemiplimab combined with platinum-based chemotherapy in advanced penile carcinoma patients.
• Treatment achieved median progression-free survival of 6.2 months and overall survival of 15.5 months, with 51.7% objective response rate at 12 weeks.
• Safety profile remained consistent with previous data, with manageable adverse events and no new safety signals identified in the 29-patient study.
© Copyright 2025. All Rights Reserved by MedPath